You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 3
  • 270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy

Citation Tools

Article menu

Download PDFPDF

E-Poster viewings
Ovarian Cancer
IGCS19-0608
270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Akaev I, Chau C, Dabab N, et al
270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy
International Journal of Gynecologic Cancer 2019;29:A114.